Russia: The inside story (PMGroup1)
Venue: Hotel Baltschug Kempinski
|Event Date/Time: Nov 02, 2011||End Date/Time: Nov 03, 2011|
The Russian pharmaceutical market has grown at nearly 20% CAGR over recent years. The government plans to increase its involvement in drug pricing, give patients more choice in terms of where and by whom they are treated, introduce GMP standards across the industry, pass a law to build better relations between the industry and the medical profession and introduce a new insurance programme.
Thatâ€™s where â€œCountry Reports...LiVE! comes in. In an invited audience of no more than 120 you will meet experts who understand both the challenges and opportunities of operating in the Russian market.
The meeting will take place in the Hotel Baltschug Kempinski, Moscow on Wednesday 2nd and Thursday 3rd of November 2011. It will begin with a welcome reception and dinner, followed by a full day of sessions, focusing on the key issues in the Russian Market.
The cost for the delegate package will be â‚¬1,770 to include all meals, and overnight accommodation on 2nd November, with an â€œearly birdâ€ rate of â‚¬1,540 for those expressing interest and confirming booking by 31st July.
The State of the Nation: Pharma 2020 â€“ What impact will government plans to increase domestic drug manufacture have on the market and what effect will the introduction of an ethics committee have on the business landscape?
Healthcare system â€“ Privatisation of State healthcare facilities is looming on the horizon along with new laws enabling patients to choose their doctor under the familiar Western maxim â€˜the money follows the patientâ€™. What will these reforms mean for the pharma industry? Can partnerships be forged in this new environment?
Market access â€“ How can pharma companies navigate the complex multi-tiered market access landscape? How can Western companies compete in an austere market where domestic manufacturers are favoured?
Pricing & reimbursement â€“ How can pharma get a seat at the negotiating table as the government plans to increase its involvement in drug pricing?
Disease burden â€“ Diabetes, heart disease and early death, often caused by alcoholism, present significant treatment challenges in Russia where a large proportion of the population self treat.
Other key issues include health economics and the regulatory environment.